Meta-analysis of concomitant mitral valve repair and coronary artery bypass surgery versus isolated coronary artery bypass surgery in patients with moderate ischaemic mitral regurgitationaEuro

被引:24
作者
Kopjar, Tomislav [1 ]
Gasparovic, Hrvoje [1 ]
Mestres, Carlos A. [2 ]
Milicic, Davor [3 ]
Biocina, Bojan [1 ]
机构
[1] Univ Zagreb, Sch Med, Dept Cardiac Surg, Univ Hosp Ctr Zagreb, Kispaticeva 12, Zagreb 10000, Croatia
[2] Cleveland Clin Abu Dhabi, Inst Heart & Vasc, Abu Dhabi, U Arab Emirates
[3] Univ Zagreb, Sch Med, Dept Cardiovasc Dis, Univ Hosp Ctr Zagreb, Zagreb, Croatia
关键词
Ischaemic mitral regurgitation; Mitral valve repair; Coronary bypass; Outcomes; Meta-analysis; LONG-TERM SURVIVAL; SURGICAL REVASCULARIZATION; HEART-FAILURE; ANNULOPLASTY; REPLACEMENT;
D O I
10.1093/ejcts/ezw022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ischaemic mitral regurgitation (IMR) is a complication of coronary artery disease with normal chordal and leaflet morphology. Controversy surrounds the issue of appropriate surgical management of moderate IMR. With the present meta-analysis, we aimed to determine whether the addition of mitral valve (MV) repair to coronary artery bypass grafting (CABG) improved clinical outcome over CABG alone in patients with moderate IMR. Databases were searched for studies reporting on clinical outcomes after CABG and MV repair or CABG alone for moderate IMR. Clinical end-points were operative mortality, survival, New York Heart Association (NYHA) class a parts per thousand yen2 and MR grade a parts per thousand yen2 at last follow-up. A total of five observational and four randomized controlled trials (RCTs) were identified. The mean follow-up was 2.7 years. An analysis of all studies revealed increased operative risk in the concomitant CABG and MV repair group {risk ratio [RR] 2.02 [95% confidence interval (CI) 1.15, 3.56],P = 0.01,I-2 = 0%}. However, an analysis of RCTs only showed that the operative risk was equivalent [RR 1.05 (95% CI 0.34, 3.30),P = 0.93,I-2 = 0%]. Pooled hazard ratio (HR) on survival did not favour either procedure [all studies: HR 1.08 (95% CI 0.77, 1.50),P = 0.66,I-2 = 0%; RCTs only: HR 0.89 (95% CI 0.47, 1.70),P = 0.73,I-2 = 0%]. The incidence of exercise intolerance quantified as NYHA class a parts per thousand yen2 was similar between groups (all studies: RR 0.72 (95% CI 0.42, 1.24),P = 0.24,I-2 = 77%; RCTs only: RR 0.61 (95% CI 0.24, 1.55),P = 0.30,I-2 = 83%]. Risk of residual MR grade a parts per thousand yen2 was higher in the CABG only group [all studies: RR 0.30 (95% CI 0.16, 0.60),P < 0.001,I-2 = 83%; RCTs only: RR 0.20 (95% CI 0.04, 0.90),P = 0.04,I-2 = 72%]. There is neither increased operative mortality nor survival benefit associated with concomitant CABG and MV repair for IMR of moderate degree over CABG alone. Further studies with long-term follow-up data and sub-group analyses of current data are needed to define a subset of patients whose survival and functional status may improve with the concomitant MV repair.
引用
收藏
页码:212 / 222
页数:11
相关论文
共 50 条
[41]   Timing of coronary artery bypass graft surgery for acute myocardial infarction patients: A meta-analysis [J].
Chen, Hong-Lin ;
Liu, Kun .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 177 (01) :53-56
[42]   The Kay Mitral Valve Repair in Coronary Artery Disease Concomitant With Ischemic Mitral Regurgitation [J].
Moeinipour, Aliasghar ;
Akbari, Mohamadreza ;
Ghorbanzadeh, Atefeh ;
Fazlinejad, Freshteh ;
Mirshahpanah, Morteza ;
Naserifar, Zahra ;
Hoseinikhah, Hamid ;
Porshokoh, Reza Tarjoman .
IRANIAN HEART JOURNAL, 2018, 19 (03) :6-14
[43]   Assessment of early outcome of coronary artery bypass grafting with and without mitral valve surgery in moderate ischemic mitral regurgitation: A multicenter comparative cohort study [J].
Ali, Mohamed Abdelfatah ;
Mohammed, Morsi A. ;
Elayouty, Hamdy Dosoky ;
Amr, Mohamed A. ;
Fayad, Elsayed A. .
EGYPTIAN JOURNAL OF SURGERY, 2024, 43 (03) :939-946
[44]   Concomitant tricuspid valve repair for mild-moderate tricuspid regurgitation patients undergoing mitral valve surgery? A meta-analysis and meta-regression [J].
Awad, Ahmed K. ;
Sayed, Ahmed ;
Elbadawy, Merihan A. ;
Ahmed, Adham ;
Wang, Tom K. Ming ;
Elgharably, Haytham .
JOURNAL OF CARDIOVASCULAR SURGERY, 2023, 64 (06) :657-667
[45]   On-Pump versus Off-Pump Coronary-Artery Bypass Surgery: a Meta-Analysis [J].
Godinho, Ana Sofia ;
Alves, Ana Sofia ;
Pereira, Alexandre Jose ;
Pereira, Telmo Santos .
ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2012, 98 (01) :87-93
[46]   A Meta-Analysis of Endoscopic Versus Conventional Open Radial Artery Harvesting for Coronary Artery Bypass Graft Surgery [J].
Cao, Christopher ;
Tian, David H. ;
Ang, Su C. ;
Peeceeyen, Sheen ;
Allan, James ;
Fu, Benjamin ;
Yan, Tristan D. .
INNOVATIONS-TECHNOLOGY AND TECHNIQUES IN CARDIOTHORACIC AND VASCULAR SURGERY, 2014, 9 (04) :269-275
[47]   Concomitant atrial fibrillation ablation in patients undergoing coronary artery bypass and cardiac valve surgery [J].
Churyla, Andrei ;
Desai, Anand ;
Kruse, Jane ;
Cox, James ;
McCarthy, Patrick .
JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2020, 31 (08) :2172-2178
[48]   Transcatheter vs. surgical mitral valve interventions in patients with prior coronary artery bypass grafting [J].
Ismayl, Mahmoud ;
Ahmed, Hasaan ;
Goldsweig, Andrew M. ;
Alkhouli, Mohamad ;
Eleid, Mackram F. ;
Rihal, Charanjit S. ;
Guerrero, Mayra .
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2024,
[49]   Comparative Effectiveness of Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Intervention for Patients With Coronary Artery Disease: A Meta-Analysis of Randomized Clinical Trials [J].
Shaik, Tanveer Ahamad ;
Chaudhari, Sandipkumar S. ;
Haider, Taimur ;
Rukia, Ramza ;
Al Barznji, Saman ;
Kataria, Heemali ;
Nepal, Laxman ;
Amin, Adil .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)
[50]   Clinical Outcomes of Patients with Coronary Artery Diseases and Moderate Left Ventricular Dysfunction: Percutaneous Coronary Intervention versus Coronary Artery Bypass Graft Surgery [J].
Wang, Shaoping ;
Lyu, Yi ;
Cheng, Shujuan ;
Liu, Jinghua ;
Borah, Bijan J. .
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2021, 17 :1103-1111